DnB Asset Management’s Arbutus Biopharma ABUS Stock Holding History

DnB Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$70.3K	Hold	14,643	–	–	﹤0.01%	1270
2026 Q1	$65.9K	Buy	+14,643	New	+$64K	﹤0.01%	1227

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DnB Asset Management's ABUS Position: Q2 2026 in Review

DnB Asset Management held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 14,643 shares worth $70.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

DnB Asset Management first reported a position in ABUS in Q1 2026 and has held it in 2 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

DnB Asset Management held 14,643 shares of Arbutus Biopharma worth $70.3K as of Q2 2026.
DnB Asset Management left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #1270 holding.
DnB Asset Management first reported a position in Arbutus Biopharma in Q1 2026 and has held it in 2 quarters since.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.